Production line readiness for high value SAMBA point-of-care Nucleic acid diagnostic test cartridge production.

DRW正在营销一种简单、强大的医疗点核酸诊断平台，称为Samba，它允许在发展中国家的偏远、资源有限的环境和发达国家的初级保健环境中进行复杂的高性能测试。第一批Samba检测是针对艾滋病毒的：一项是测量艾滋病毒病毒载量用于治疗监测，另一项是检测婴儿中的艾滋病毒以便开始早期治疗。由于世卫组织对撒哈拉以南非洲的病毒载量监测和早期婴儿诊断的建议，到2017年，仅发展中国家的市场就将增长到10亿美元/年。为了满足需求，DRW必须使其测试盒制造自动化，以实现每年150万次测试的生产规模。DRW建议并要求提供资金，用于开发适合高速组装和100%检查的生产工艺，以便为发达和发展中的世界市场生产Samba测试。

DRW is marketing a simple, robust point-of-care nucleic acid diagnostic platform, called SAMBA, which allows complex, high-performance tests to be carried out in remote, resource-limited settings in developing countries and primary care settings in developed countries. The first SAMBA tests are for HIV: one to measure HIV viral load for treatment monitoring and one to detect HIV in infants in order to initiate early treatment. Due to WHO recommendation for viral load monitoring and early infant diagnosis in sub-Saharan Africa, the market in the developing world alone will grow to $1 billion/annum by 2017. To meet demand, DRW must automate its test cartridge manufacture to allow a production scale of 1.5 million tests/annum. DRW proposes and requests funding for developing production processes that are appropriate for high-speed assembly and 100% inspection, to produce SAMBA tests for the developed and developing world market.